Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tijl Huijbregts"'
Autor:
Marco Timmers, Gijs Verheijden, Guy de Roo, Michel Eppink, Vincent de Groot, Tijl Huijbregts, Henri Spijker, John Joosten, Wiro Menge, Ronald Elgersma, Ruud Coumans, Patrick Beusker, Patrick Groothuis, Ellen Mattaar, David Egging, Diels van den Dobbelsteen, Eline Loosveld, Danielle Jacobs, Tanja van Achterberg, Monique van der Vleuten, Miranda van der Lee, Ruud Ubink, Wim Dokter
Supplementary tables describe a comparison of half-lives of SYD983 in the different species (Table S1), PK details in mice (Table S2), PK details in tumor-bearing mice (Table S3), PK details in cynomolgus monkeys (Tables S4 and S5), Flow rates of SYD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::577fecc3721cf52f00190b2f91911f37
https://doi.org/10.1158/1535-7163.22502829.v1
https://doi.org/10.1158/1535-7163.22502829.v1
Autor:
Marco Timmers, Gijs Verheijden, Guy de Roo, Michel Eppink, Vincent de Groot, Tijl Huijbregts, Henri Spijker, John Joosten, Wiro Menge, Ronald Elgersma, Ruud Coumans, Patrick Beusker, Patrick Groothuis, Ellen Mattaar, David Egging, Diels van den Dobbelsteen, Eline Loosveld, Danielle Jacobs, Tanja van Achterberg, Monique van der Vleuten, Miranda van der Lee, Ruud Ubink, Wim Dokter
Details are given of the synthesis of SYD983 and the non-binding control, preparation of fluorescently-labeled SYD983, bioanalysis of SYD983 using SEC, HIC, and RP-HPLC, functional assays like an ADCC assay and internalization, and details on the PK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d71b8b769e05a9d69d5154dd46d72d7
https://doi.org/10.1158/1535-7163.22502832.v1
https://doi.org/10.1158/1535-7163.22502832.v1
Autor:
C. Marco Timmers, Tijl Huijbregts, Ronald Christiaan Elgersma, Franciscus M. H. de Groot, GF Verheijden, Ruud Coumans, Patrick Henry Beusker, Jacques M. Lemmens, David F. Egging, Diels van den Dobbelsteen, Miranda M.C. van der Lee, Ruud Ubink, Wim H. A. Dokter, Wiro Michaël Petrus Bernardus Menge, Henri Johannes Spijker, John Joosten
Publikováno v:
Molecular Pharmaceutics. 12:1813-1835
Antibody-drug conjugates (ADCs) that are currently on the market or in clinical trials are predominantly based on two drug classes: auristatins and maytansinoids. Both are tubulin binders and block the cell in its progression through mitosis. We set
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d112fc7f8b9f7d0584c7c81aa6b00e7
https://doi.org/10.1021/mp500781a
https://doi.org/10.1021/mp500781a
Autor:
Vincent F.M.H. De Groot, Gijs Verheijden, Monique van der Vleuten, Ruud Ubink, Tanja van Achterberg, Eline Loosveld, Wiro Michaël Petrus Bernardus Menge, Henri Johannes Spijker, Tijl Huijbregts, Marco Timmers, Ronald Christiaan Elgersma, Diels van den Dobbelsteen, Wim H. A. Dokter, Michel H.M. Eppink, Ruud Coumans, Danielle Jacobs, Ellen Mattaar, David F. Egging, Miranda van der Lee, John Joosten, Patrick Beusker, Guy de Roo, Patrick Groothuis
Publikováno v:
Molecular Cancer Therapeutics, 13, 2618-2629
Molecular Cancer Therapeutics 13 (2014)
Molecular Cancer Therapeutics 13 (2014)
A linker-drug platform was built on the basis of a cleavable linker-duocarmycin payload for the development of new-generation antibody–drug conjugates (ADC). A leading ADC originating from that platform is SYD983, a HER2-targeting ADC based on tras
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee6605a6844a687667fb0a9a10c6e87f
https://doi.org/10.1158/1535-7163.mct-14-0040-t
https://doi.org/10.1158/1535-7163.mct-14-0040-t